Get the Stockscreener App
0.2138
3.43%
-0.0076
Pre-market:
.21
-0.0038
-1.78%
Genprex Inc stock is traded at $0.2138, with a volume of 812.47K.
It is down -3.43% in the last 24 hours and down -20.22% over the past month.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
See More
Previous Close:
$0.2214
Open:
$0.22
24h Volume:
812.47K
Relative Volume:
0.41
Market Cap:
$7.09M
Revenue:
-
Net Income/Loss:
$-22.71M
P/E Ratio:
-0.0183
EPS:
-11.71
Net Cash Flow:
$-18.24M
1W Performance:
-7.45%
1M Performance:
-20.22%
6M Performance:
-55.73%
1Y Performance:
-84.94%
1-Day Range:
$0.209
$0.226
1-Week Range:
$0.209
$0.2593
52-Week Range:
$0.2023
$3.97
Genprex Inc Stock (GNPX) Company Profile
Name
Genprex Inc
Sector
Industry
Phone
512-537-7997
Address
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
0.2138 | 7.36M | 0 | -22.71M | -18.24M | -11.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-21 | Initiated | National Securities | Buy |
| Apr-29-19 | Initiated | Noble Capital Markets | Outperform |
Genprex Inc Stock (GNPX) Latest News
Is this a good reentry point in Genprex Inc.Free Capital Efficiency Optimized Stock Alerts - Newser
Using fundamentals and technicals on Genprex Inc.Buy Strategy Tracker with Growth Indicators - Newser
Quant Strategy Flags Genprex Inc. for EntryCommunity Shared Smart Money Signals Show Movement - beatles.ru
Predicting Genprex Inc. trend using moving averagesPrice Action Summary and Entry Strategy Guide - Newser
Is Genprex Inc. stock bottoming outWeekly Price Target Forecast and Alerts - Newser
Detecting support and resistance levels for Genprex Inc.Daily Trade Setup Forecast with Confidence - Newser
Is Genprex Inc. stock a top performer YTDBest Stocks for Rapid Income - thegnnews.com
Technical analysis overview for Genprex Inc. stockFree Weekly Stock Watch With Growth Focus - Newser
Applying chart zones and confluence areas to Genprex Inc.Free Consistent Profit Pattern Recognition Tools - Newser
Multi factor analysis applied to Genprex Inc.Alpha Stock Picks with Chart Confirmation - Newser
Genprex GNPX 2025Q2 Earnings Preview Upside Ahead on Diabetes Gene Therapy Advancements - AInvest
How to build a custom watchlist for Genprex Inc.Portfolio Safety Metrics and Return Analysis - Newser
Genprex Issues Stockholder Letter And Provides 2025 Corporate Update - TradingView
Genprex Announces Stockholder Letter and Corporate Update - TipRanks
Genprex Achieves Major Clinical Milestones: CEO Reveals Ambitious Plans for Cancer and Diabetes Gene Therapies - Stock Titan
Genprex Inc. Rebounds From Oversold Zone — Now WhatPattern Alert With ROI Driven Strategy Shared - metal.it
How strong is Genprex Inc. company’s balance sheetOverwhelming profit margins - Jammu Links News
Is it the right time to buy Genprex Inc. stockBuild a winning investment strategy today - Jammu Links News
Should I hold or sell Genprex Inc. stock in 2025Discover high-impact investment opportunities - Jammu Links News
How many analysts rate Genprex Inc. as a “Buy”Get high-impact stock recommendations now - Jammu Links News
What catalysts could drive Genprex Inc. stock higher in 2025Free Stock Market Query - Jammu Links News
How volatile is Genprex Inc. stock compared to the marketBuild a portfolio for long-term financial success - Jammu Links News
Is Genprex Inc. stock overvalued or undervaluedExceptional risk-adjusted gains - Jammu Links News
What are the latest earnings results for Genprex Inc.Invest confidently with professional guidance - Jammu Links News
When is Genprex Inc. stock expected to show significant growthAchieve consistent high returns with low risk - Jammu Links News
What makes Genprex Inc. stock price move sharplySuperior profit margins - Jammu Links News
What is the dividend policy of Genprex Inc. stockUnlock exclusive trading strategies for gains - Jammu Links News
What institutional investors are buying Genprex Inc. stockExpert guidance for superior capital growth - Jammu Links News
Is Genprex Inc. a growth stock or a value stockBuild a diversified portfolio for risk mitigation - Jammu Links News
Price action breakdown for Genprex Inc.Weekly Return Plan for Conservative Traders - Newser
Will Genprex Inc. stock benefit from interest rate changesFree Daily Volume Spike Trading Signals - Newser
Relative strength of Genprex Inc. in sector analysisROI Focused Watchlist with Trade Confidence - Newser
Genprex (GNPX) to Release Quarterly Earnings on Friday - Defense World
Is Genprex Inc. stock reversal real or fakeFree Entry Zone Strategy for Consistent Profit - Newser
Is Genprex Inc. forming a reversal patternAI Risk Optimized Trade Forecast Planner - Newser
Does Genprex Inc. stock perform well during market downturnsExpert Picks Tracker For Beginners - Jammu Links News
Genprex Inc: Weathering Stock Market Storms with 7.85M Market Cap - investchronicle.com
Genprex Inc. stock trend forecastDaily Profit Watch With Forecast Confidence - Newser
Why Genprex Inc. stock attracts strong analyst attentionFundamental + Technical Hybrid Stock Tips Shared - beatles.ru
Genprex Inc. At Decision Level — Rebound or ResistanceWealth Building Stock Market Ideas Based on Momentum - beatles.ru
Genprex Inc Stock (GNPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
3.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):